ARQL at 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Pharma, I would like to know your thoughts on these abstracts. I have my ideas but not being a scientist I won't comment. Pharma, I must say your writing style and thought process reminds me a lot of someone that used to post on these boards several years back.....MH00034. I miss hearing from him.
Here are the two posters ARQL will have. First one on Nov 8 is: Combination Effect of Tivantinib with Erlotinib On Cell Proliferation, C-Met Signals and Apoptosis in a Human Non-small Cell Lung Cancer Cell Line
Second one on Nov 9th is: Relationship Between Tumor MET Expression and Clinical Outcomes in Cancer Patients Treated with Tivantinib
If you Google the congress you can see the abstracts in the searchable program.
Yes, it is this year. just Google "24th EORTC-NCI-AACR Symposium" and it will be the first link you see. Once at the site click on "Searchable Programme". Use Tivantinib as the search word and you will see the two posters.
As for Pucci, he collects superhigh pay and runs double-blind Ph2 trials. This is great for him: nothing to do for two years just making presentations from time to time in a broken English nobody can understand what he is talking about.
It is a good time for the management get off their fat #$%$ and put some efforts into pipeline development efforts.